Twist Bioscience (TWST) COO Finn Sells $302K of Stock

On October 23, 2026, Patrick John Finn, President and COO of Twist Bioscience Corporation (TWST), sold 2,245 shares for about $302,152. This transaction was reported in a Form 4 filing with the SEC. After the sale, Finn holds 182,843 shares, reflecting a 1.21% decrease in his stake.

TWST Twist Bioscience Corporation

$159.85 ▲ +393.52% year to date

1M 3M YTD

Daily close · Oct 27, 2026

Inside Patrick John Finn's Trade

Finn sold his shares at an average price of $134.59 on the day of the sale. The stock closed at $139.92 on the same day, showing a notable difference in price. This trade was not part of a planned sale.

Other Institutional Activity in Twist Bioscience

Several institutional investors have adjusted their positions in Twist Bioscience recently. Artisan Partners Limited Partnership reduced its stake by 1,565,861 shares, now holding 4,802,017 shares worth about $767.6 million. Similarly, ARK Investment Management, LLC cut its holdings by 1,793,154 shares, ending with 4,549,803 shares valued at approximately $727.3 million. Edgepoint Investment Group Inc. and William Blair Investment Management, LLC also decreased their positions, holding 2,521,635 shares and 2,174,594 shares, respectively.

Twist Bioscience Corporation Stock Up 10.1%

As of October 27, 2026, Twist Bioscience shares traded recently around $159.85, which is about 14.2% above the closing price of $139.92 on October 23. The stock is currently above its 50-day moving average by 6.4% and significantly above its 200-day average by 84.8%. However, it remains 27.2% below its 52-week high of $219.71.

Recent Earnings

Twist Bioscience reported trailing twelve-month revenue of $431.8 million, with a year-over-year revenue growth of 23.2%. The company's next earnings report is scheduled for November 12, 2026.

Insider Buying and Selling at Twist Bioscience Corporation

In recent insider activity, several executives sold shares of Twist Bioscience. On October 2, 2026, Paula Green sold 10,088 shares for about $1.9 million, while Robert F. Werner sold 1,482 shares for approximately $279,926. CEO Emily Leproust also sold 4,548 shares on October 5, and CFO Adam Laponis sold 2,462 shares on October 9.

Analysts Set New Price Targets

On October 1, 2026, Guggenheim maintained its 'Buy' rating on Twist Bioscience with a price target of $212. Barclays followed on October 7, also maintaining an 'Overweight' rating with a target of $215. Jefferies initiated coverage with a 'Hold' rating and a target of $150 on October 8. Overall, the consensus among analysts remains a 'Buy' with a mean price target of $168.25.

About Twist Bioscience

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products, serving various sectors in healthcare and biotechnology. With a market cap of approximately $10.6 billion, the company is well-positioned in the growing biotech industry.

Bottom Line

Investors should keep an eye on Twist Bioscience's upcoming earnings report on November 12, 2026, and any further insider transactions. Finn's recent sale adds to a trend of insider selling at the company, which could be significant as the stock approaches analyst price targets.